A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

Trial Profile

A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs JKB 122 (Primary)
  • Indications Autoimmune hepatitis
  • Focus Therapeutic Use
  • Acronyms JKB-122AIH
  • Sponsors TaiwanJ Pharmaceuticals
  • Most Recent Events

    • 24 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 05 Nov 2015 According to a TaiwanJ Pharmaceuticals media release, company Gains FDA Approval for Entering Phase 2 Clinical Study on Autoimmune Hepatitis.
    • 25 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top